AcquisitionsJun 25, 2026, 08:26 AM
Merck KGaA to Acquire Bio-Techne for $11.3B, $73/Share
AI Summary
Merck KGaA, Darmstadt, Germany, has agreed to acquire Bio-Techne Corporation for $73 per share in cash, valuing the company at approximately $11.3 billion. This represents a 36% premium to Bio-Techne's recent trading price. The acquisition is expected to immediately boost Merck KGaA's sales growth and EBITDA pre margin, with anticipated annual cost synergies of EUR 140 million by the third year post-closing. The deal aims to strengthen Merck KGaA's position in fast-growing life science markets, including multi-omics, spatial biology, and cell and gene therapy, by integrating Bio-Techne's portfolio of life science tools and analytical technologies.
Key Highlights
- Merck KGaA will acquire Bio-Techne for $73 per share in cash.
- The total enterprise value of the acquisition is approximately $11.3 billion (EUR 9.9 billion).
- The offer represents a 36% premium to Bio-Techne's one-month volume weighted average trading price.
- The acquisition is expected to be immediately accretive to sales growth and EBITDA pre margin post-closing.
- Merck KGaA anticipates annual cost synergies of approximately EUR 140 million by year 3 after closing.
- The deal strengthens Merck KGaA's leadership in high-growth life science markets, including multi-omics and cell/gene therapy.
- Bio-Techne reported net sales of over $1.2 billion in fiscal year 2025.
- The transaction is expected to close by late 2026 or early 2027, subject to customary approvals.
Price Impact
More from TECH